Market News
Recent Developments:
New product launches/approval:
- In May 2022, VYNE Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults
- In June 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced the U.S. launch of its generic version of once daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea
Acquisition and partnerships:
- In September 2023, Mayne Pharma, a pharmaceutical company, reimagined its business to focus on dermatology and other core businesses. In line with that, the company has entered into an asset purchase agreement to acquire the global rights to the rosacea treatment RHOFADE (oxymetazoline hydrochloride) cream from medical dermatology companies Novan, a medical dermatology company, and its subsidiary EPI Health
- In June 2021, Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced an agreement with Dr. Reddy’s Laboratories Ltd., a leading multinational pharmaceutical company, for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey Medical has acquired global commercialization rights including the U.S. and Europe, except that Dr. Reddy’s has retained certain rights to the program in select markets including Brazil, Russia, India and China
Top Companies in Global Rosacea Treatment Market:
- Galderma
- Allergan
- Bayer
- Foamix Pharmaceuticals
- Mayne Pharma
- Leo Pharma
- Pfizer
- Dermira
- Nestlé Skin Health
- Aclaris Therapeutics
U.S.: 
U.K. : 
India : 
